Generic name: efavirenz + tenofovir disoproxil fumarate + emtricitabine
Company: Bristol-Myers Squibb and Gilead Sciences
Approval status: approved
Generic version available: yes
An alternative treatment regimen for people who are virgin to antiretroviral therapies living with HIV, as directed by the US Department of Health and Human Services (DHHS)
Atripla is a single pill regimen for HIV. It contains two different types of HIV drugs: a non-nucleoside reverse transcriptase inhibitor and two nucleoside reverse transcriptase inhibitors. Atripla was approved by the US Food and Drug Administration for use by people living with HIV in July 2006. The
Atripla is a combination of three drugs: Sustiva (efavirenz), Viread (tenofovir disoproxil fumarate) and Emtriva (emtricitabine). All three drugs can be purchased individually for use in combination with other HIV drugs.
Adult dose: One tablet once a day. Each tablet contains 600 mg of efavirenz + 300 mg of tenofovir disoproxil fumarate + 200 mg of emtricitabine.
Pediatric dose: 12 to 18 years old and weighing at least 88 kg (40 kg): one tablet once a day.
Dosage information: This is a complete regimen of one tablet, once a day. Take on an empty stomach. The dose should be taken at bedtime to minimize dizziness, drowsiness and decreased concentration.
A lot, but a lot of attention even to the next stretch !!!
Many patients experience dizziness, headache, difficulty sleeping, drowsiness, difficulty concentrating and / or unusual dreams after starting treatment with Atripla. These feelings may be less insistent if you take Atripla at bedtime on an empty stomach. They also tend to disappear after you take the medicine for a few weeks. Tell your doctor immediately if any of these side effects persist or bother you.
A small number of patients had severe depression, strange thoughts or irritated behavior while taking Sustiva, one of Atripla's medicines. Some patients have had thoughts of suicide and some have actually committed suicide.
These problems tend to occur more frequently in patients with a history of mental illness. You should contact your doctor immediately if you think you are experiencing these symptoms, so that he can decide whether to continue taking Sustiva.
Skin rash is another common side effect of Atripla. These skin rashes usually go away without any change in treatment. In a small number of patients, the rash can be severe. If you develop a rash, call your doctor as soon as possible.
Atripla can lead to new or worsening kidney problems, including kidney failure. Your doctor may do blood tests to check your kidneys before and during treatment with Atripla. If you develop kidney problems, your doctor may need to make changes to your treatment regimen.
Atripla can lead to bone problems, including bone pain or soft or thin bones, which can lead to fractures. Your doctor can do tests to check your bones.
If you also have the hepatitis B virus (HBV) and take Atripla, your hepatitis may get worse if you stop taking it. Do not stop taking Atripla without talking to your doctor first.
These medications should not be taken with the following medications while being treated with Atripla®:
- Antibiotics: Priftin (Rifapentin)
- Antifungals: standard doses of Vfend (voriconazole)
- Antihistamines: Hismanal (astemizole) or Seldane (terfenadine)
- antipsychotics: Orap (Pimozid)
- Acid reflux / heartburn medications: Propulsid (Cisapride)
- Heart medications: Vascor (bepridil)
- Sedatives: Versed (midazolam) and Halcion (triazolam)
- Antimigraine medications: Wigraine and Cafergot (medicines for ergot)
- Antivirals: Hepsera (adefovir)
Atripla must not be used na at the same time as Vfend (a voriconazole), a medicine used for certain fungal infections. Efavirenz in Atripla can significantly decrease the effectiveness of Vfend; Vfend can significantly increase the risk of efavirenz side effects.
Atripla should not be combined with any HIV medicine that contains any of the active ingredients in Atripla. They include: Complera, Emtriva, Genvoya, Stribild, Sustiva or Viread. The combination of Atripla with HIV medicines containing active ingredients similar to Atripla should also be avoided. They include: Combivir, Epivir, Epzicom, Rescriptor, Triumeq, Trizivir and Viramune.
Other medicines that can be avoided during treatment with Atripla: Fortovase, Invirase (saquinavir), Biaxin (clarithromycin), Noxafil (posaconazole) and Sporanox (itraconazole).
Important drug interactions for the treatment of hepatitis C: Can be combined with Sovaldi (sofosbuvir), Harvoni (ledipasvir / sofosbuvir), ribavirin and pegylated interferon alfa. Do not use with Olysio / Sovriad (simeprevir) or Viekira Pak (ombitasvir / paritaprevir / ritonavir / dasabuvir).
Dose modifications to the following medications may be necessary, if combined with Atripla: calcium channel blockers, such as Cardizem or Tiazac (diltiazem), Covera HS or Isoptin (verapamil) and others; Crixivan (indinavir), Selzentry (maraviroc); immunosuppressive drugs cyclosporine (Gengraf, Neoral, Sandimmune and others), Prograf (tacrolimus) or Rapamune (sirolimus); Methadone; Mycobutin (rifabutin); Rifampicin; cholesterol-lowering drugs, such as Lipitor (atorvastatin), Pravachol (pravastatin) and Zocor (simvastatin); or the antidepressant drugs bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL and Zyban) or Zoloft (sertraline).
Other drug interactions are possible. See the Atripla brochure for more details: http://packageinserts.bms.com/pi/pi_atripla.pdf
Before taking this medicine, tell your doctor if you have kidney, liver disease (including hepatitis B) or a history of depression / suicidal thoughts. Also, tell your doctor if you are pregnant or planning to become pregnant, if you are breastfeeding and all your medical conditions, including all prescription and over-the-counter medications and supplements.
Information about the patient care program: https://www.poz.com/basics/hiv-basics/drug-assistance-programs
Translated by Cláudio Souza from the original POZ in Atripla There is no information about the author or editor of the text